Twist Bioscience (TWST) Operating Leases (2019 - 2026)

Twist Bioscience (TWST) has reported Operating Leases for 8 consecutive years, with $93.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases rose 19.76% year-over-year to $93.6 million in Q2 2026; TTM through Jun 2026 was $93.6 million, a 19.76% increase from a year earlier, with the FY2025 full-year figure at $61.8 million, down 12.06% from the prior year.
• Operating Leases was $93.6 million for Q2 2026 at Twist Bioscience, down from $95.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $98.0 million in Q4 2025 and troughed at $61.8 million in Q3 2025.
• A 5-year average of $84.8 million and a median of $84.9 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 258.13% in 2022 and retreated 12.06% in 2025, its largest moves.
• Over 5 years, Operating Leases stood at $94.0 million in 2022, then fell by 2.23% to $91.9 million in 2023, then slipped by 10.08% to $82.6 million in 2024, then increased by 18.68% to $98.0 million in 2025, then retreated by 4.55% to $93.6 million in 2026.
• The last three Operating Leases figures came in at $93.6 million (Q2 2026), $95.8 million (Q1 2026), and $98.0 million (Q4 2025), per Business Quant data.